We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
Read MoreHide Full Article
GSK plc (GSK - Free Report) announced positive headline data from the phase III GLISTEN study, which is evaluating its investigational targeted inhibitor of the ileal bile acid transporter (IBAT), linerixibat, for treating adult patients with cholestatic pruritus associated with primary biliary cholangitis (PBC).
The global GLISTEN study met its primary endpoint by showing that treatment with linerixibat led to a statistically significant improvement in monthly itch score as compared with placebo over 24 weeks.
Per management, if successfully developed, linerixibat has the potential to become the first therapy indicated for treating itch associated with PBC globally.
Year to date, shares of GSK have lost 9.7% compared with the industry’s decline of 11.1%.
Image Source: Zacks Investment Research
More on GSK's GLISTEN Study
The preliminary safety data from the ongoing GLISTEN study were similar to those seen in previous studies on linerixibat.
Full data from the GLISTEN study is expected to be presented at a medical conference in the future.
Cholestatic pruritus (relentless itch) is one of the most common symptoms of PBC, a rare autoimmune disease that might lead to liver failure.
Per the press release, by the year 2030, patients diagnosed with PBC will reach 510,000 globally and over 240,000 people will experience relentless itch, for which there is currently no cure.
Other Players in the PBC Market
Given the high unmet medical need, a few other companies are also developing treatments for PBC, as there remains a high unmet medical need.
In August 2024, the FDA granted accelerated approval to Gilead Sciences’ (GILD - Free Report) seladelpar for the treatment of PBC, in combination with ursodeoxycholic acid (UDCA), in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
The candidate was approved under the brand name Livdelzi.
Seladelpar was added to GILD’s portfolio/pipeline through the acquisition of CymaBay Therapeutics Inc. for $4.3 billion in March 2024. The approval of Livdelzi strengthened GILD’s liver disease portfolio.
Small biotech Mirum Pharmaceuticals (MIRM - Free Report) is developing its pipeline candidate, volixibat, also an oral IBAT inhibitor, for the treatment of PBC.
The phase IIb VANTAGE study is currently evaluating MIRM’s volixibat for treating PBC.
In June 2024, Mirum announced positive interim data from the VANTAGE study, which showed that treatment with volixibat led to statistically significant improvement in pruritus as well as meaningful reductions in serum bile acids and also an improvement in fatigue.
In the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time. Year to date, shares of CSTL have surged 29.3%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
GSK plc (GSK - Free Report) announced positive headline data from the phase III GLISTEN study, which is evaluating its investigational targeted inhibitor of the ileal bile acid transporter (IBAT), linerixibat, for treating adult patients with cholestatic pruritus associated with primary biliary cholangitis (PBC).
The global GLISTEN study met its primary endpoint by showing that treatment with linerixibat led to a statistically significant improvement in monthly itch score as compared with placebo over 24 weeks.
Per management, if successfully developed, linerixibat has the potential to become the first therapy indicated for treating itch associated with PBC globally.
Year to date, shares of GSK have lost 9.7% compared with the industry’s decline of 11.1%.
Image Source: Zacks Investment Research
More on GSK's GLISTEN Study
The preliminary safety data from the ongoing GLISTEN study were similar to those seen in previous studies on linerixibat.
Full data from the GLISTEN study is expected to be presented at a medical conference in the future.
Cholestatic pruritus (relentless itch) is one of the most common symptoms of PBC, a rare autoimmune disease that might lead to liver failure.
Per the press release, by the year 2030, patients diagnosed with PBC will reach 510,000 globally and over 240,000 people will experience relentless itch, for which there is currently no cure.
Other Players in the PBC Market
Given the high unmet medical need, a few other companies are also developing treatments for PBC, as there remains a high unmet medical need.
In August 2024, the FDA granted accelerated approval to Gilead Sciences’ (GILD - Free Report) seladelpar for the treatment of PBC, in combination with ursodeoxycholic acid (UDCA), in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
The candidate was approved under the brand name Livdelzi.
Seladelpar was added to GILD’s portfolio/pipeline through the acquisition of CymaBay Therapeutics Inc. for $4.3 billion in March 2024. The approval of Livdelzi strengthened GILD’s liver disease portfolio.
Small biotech Mirum Pharmaceuticals (MIRM - Free Report) is developing its pipeline candidate, volixibat, also an oral IBAT inhibitor, for the treatment of PBC.
The phase IIb VANTAGE study is currently evaluating MIRM’s volixibat for treating PBC.
In June 2024, Mirum announced positive interim data from the VANTAGE study, which showed that treatment with volixibat led to statistically significant improvement in pruritus as well as meaningful reductions in serum bile acids and also an improvement in fatigue.
GSK's Zacks Rank & Key Pick
GSK currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the biotech sector is Castle Biosciences, Inc. (CSTL - Free Report) , carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time. Year to date, shares of CSTL have surged 29.3%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.